PAPERZILLA
Crunching Academic Papers into Bite-sized Insights.
About
Sign Out
← Back to papers
Health Sciences › Medicine › Dermatology
The global burden of atopic dermatitis: lessons from the GBD Study - 1990 to 2017
★
★
★
★
☆
SHARE
Overview
Paper Summary
Conflicts of Interest
Identified Weaknesses
Rating Explanation
Good to know
Topic Hierarchy
File Information
Paper Summary
Paperzilla title
Atopic Dermatitis: A Global Itch That Won't Go Away (But the Data Could Be Better)
Atopic dermatitis ranks 15th among non-fatal diseases globally and is the leading skin disease burden worldwide based on disability-adjusted life years (DALYs). While global DALY rates for AD remained stable from 1990-2017, prevalence is highest in early childhood with a second peak in middle age, suggesting potential shifts in disease presentation across the lifespan.
Possible Conflicts of Interest
CF is a chief investigator in several AD-related clinical trials and research projects, and his department has received funding from Sanofi-Genzyme. RD served as a medical consultant to Altus Labs and directs a research fellowship funded by Pfizer Pharmaceuticals. While these are disclosed, they represent potential conflicts of interest.
Identified Weaknesses
Data Source Limitations
Reliance on self-reported data and administrative data can introduce bias due to misclassification and underreporting.
Limited Data Granularity
The study relies on pre-existing data, which may not fully capture the complexity of AD or its impact on patients' lives.
Confounding Factors
The study acknowledges the influence of lifestyle and environmental factors but does not directly measure or control for these, limiting the ability to draw causal inferences.
Ecological Fallacy
The study relies on aggregated data, which may mask important variations within countries or regions.
Lack of Comorbidity Data
The GBD methodology does not incorporate comorbidities, which are common in AD patients and contribute significantly to their overall burden of disease.
Rating Explanation
This study provides valuable insights into the global burden of AD using a large-scale dataset. However, the reliance on secondary data and the limitations of the GBD methodology warrant a slightly lower rating. The disclosed conflicts of interest also factor into the rating.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →
Topic Hierarchy
File Information
Original Title:
The global burden of atopic dermatitis: lessons from the GBD Study - 1990 to 2017
File Name:
Laughter-etal-2020_The_global_burden_of_aptopic%20.pdf
[download]
File Size:
8.60 MB
Uploaded:
July 14, 2025 at 10:55 AM
Privacy:
🌐 Public
© 2025 Paperzilla. All rights reserved.